GlassScriptPhysician profile
Assar Ahmed Rather
NPI 1174834097
$3,558.24
in general payments reported to CMS, 2019-2025
10 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,348 · 2020: $128 · 2021: $15.08 · 2022: $39.00 · 2023: $297 · 2024: $321 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,311.81 | 2019-2020 | |
| Davol INC. | $302.56 | 2024-2025 | Phasix Mesh |
| Axonics, INC. | $297.22 | 2023 | Axonics |
| Ethicon US, LLC | $218.22 | 2020-2025 | Harmonic, Enseal, Echelon Flex |
| Medtronic, INC. | $167.47 | 2025 | Signia, Ligasure |
| Angiodynamics, INC. | $94.93 | 2021-2024 | Smart Port Ct |
| Smith+Nephew, INC. | $61.94 | 2024 | Intellio Link Werewolf |
| Abbott Laboratories | $48.21 | 2019 | |
| Integra Lifesciences Corporation | $32.87 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Takeda Pharmaceuticals U.S.A., INC. | $23.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assar Rather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.